Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters.

ABSTRACT:

Introduction

Immunocompromised patients have been shown to have an impaired immune response to COVID-19 vaccines.

Methods

Here we compared the B-cell, T-cell and neutralizing antibody response to WT and Omicron BA.2 SARS-CoV-2 virus after the fourth dose of mRNA COVID-19 vaccines in patients with hematological malignancies (HM, n=71), solid tumors (ST, n=39) and immune-rheumatological (IR, n=25) diseases. The humoral and T-cell responses to SARS-CoV-2 vaccination were analyzed by quantifying the anti-RBD antibodies, their neutralization activity and the IFN-γ released after spike specific stimulation.

Results

We show that the T-cell response is similarly boosted by the fourth dose across the different subgroups, while the antibody response is improved only in patients

SUBMITTER: Rescigno M 

PROVIDER: S-EPMC9911671 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature